Nam-Ho Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nam-Ho Kim has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Yong-Seog Oh
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
4 shared publications - Hui-Nam Pak
Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Hyoung-Seob Park
Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Keimyung University Dongsan Hospital, Keimyung University College of Medicine, Daegu, Korea
3 shared publications - Hyung Wook Park
Department of Cardiovascular Medicine, Chonnam National University Medical School, 61469 Gwangju, Republic of Korea
3 shared publications - Jong-Il Choi
Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine and Korea University Anam Hospital, Seoul, Korea
3 shared publications - Juneyoung Lee
Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (2) , 121-131
A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL
Oh IY, et al. Korean Circ J. 2024 Oct;55:e8. https://doi.org/10.4070/kcj.2024.0154
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (2) , 121-131
Open AccessA Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL
Oh IY, et al. Korean Circ J. 2024 Oct;55:e8. https://doi.org/10.4070/kcj.2024.0154
- Open Access
- 2 November 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (11)
Identification of concealed cardiomyopathy using next-generation sequencing–based genetic testing in Korean patients initially diagnosed with idiopathic ventricular fibrillation
Idiopathic ventricular fibrillation (IVF) is a disease in which the cause of ventricular fibrillation cannot be identified despite comprehensive clinical evaluation. This study aimed to investigate the clinical yield and implications of genetic testing for IVF. This study was based on the multi-centre inherited arrhythmia syndrome registry in South Korea from 2014 to 2017. Next-generation sequencing–based genetic testing was performed that included 174 genes previously linked to cardiovascular disease. A total of 96 patients were clinically diagnosed with IVF. The mean age of the onset was 41.2 ± 12.7 years, and 79 patients were males (82.3%). Of these, 74 underwent genetic testing and four (5.4%) of the IVF probands had pathogenic or likely pathogenic variants (each having one of MYBPC3, MYH7, DSP, and TNNI3). All pathogenic or likely pathogenic variants were located in genes with definite evidence of a cardiomyopathy phenotype, either hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. Next-generation sequencing–based genetic testing identified pathogenic or likely pathogenic variants in 5.4% of patients initially diagnosed with IVF, suggesting that genetic testing with definite evidence genes of cardiomyopathy may enable molecular diagnosis in a minority of patients with IVF. Further clinical evaluation and follow-up of patients with IVF with positive genotypes are needed to unveil concealed phenotypes, such as the pre-clinical phase of cardiomyopathy. Concealed channelopathy and cardiomyopathy in IVF. IVF, idiopathic ventricular fibrillation; NGS, next-generation sequencing; P/LP, pathogenic or likely pathogenic; BrS, Brugada Syndrome; LQTS, long QT syndrome; CPVT, cathecholaminergic polymorphic ventricular tachycardia; ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy.
- 2 November 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (11)
Open AccessIdentification of concealed cardiomyopathy using next-generation sequencing–based genetic testing in Korean patients initially diagnosed with idiopathic ventricular fibrillation
Idiopathic ventricular fibrillation (IVF) is a disease in which the cause of ventricular fibrillation cannot be identified despite comprehensive clinical evaluation. This study aimed to investigate the clinical yield and implications of genetic testing for IVF. This study was based on the multi-centre inherited arrhythmia syndrome registry in South Korea from 2014 to 2017. Next-generation sequencing–based genetic testing was performed that included 174 genes previously linked to cardiovascular disease. A total of 96 patients were clinically diagnosed with IVF. The mean age of the onset was 41.2 ± 12.7 years, and 79 patients were males (82.3%). Of these, 74 underwent genetic testing and four (5.4%) of the IVF probands had pathogenic or likely pathogenic variants (each having one of MYBPC3, MYH7, DSP, and TNNI3). All pathogenic or likely pathogenic variants were located in genes with definite evidence of a cardiomyopathy phenotype, either hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. Next-generation sequencing–based genetic testing identified pathogenic or likely pathogenic variants in 5.4% of patients initially diagnosed with IVF, suggesting that genetic testing with definite evidence genes of cardiomyopathy may enable molecular diagnosis in a minority of patients with IVF. Further clinical evaluation and follow-up of patients with IVF with positive genotypes are needed to unveil concealed phenotypes, such as the pre-clinical phase of cardiomyopathy. Concealed channelopathy and cardiomyopathy in IVF. IVF, idiopathic ventricular fibrillation; NGS, next-generation sequencing; P/LP, pathogenic or likely pathogenic; BrS, Brugada Syndrome; LQTS, long QT syndrome; CPVT, cathecholaminergic polymorphic ventricular tachycardia; ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy.
- Open Access
- 31 October 2023
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 5 (4) , 102-112
Decision-making for recurrent atrial fibrillation after catheter ablation
Catheter ablation for atrial fibrillation (AF), especially pulmonary vein (PV) isolation, is widely used for rhythm control. However, AF recurrence remains a challenge, affecting 20% to 50% of cases. This review focuses on AF recurrence after catheter ablation. AF recurrence can be categorized into early recurrence (ER) within 3 months after index procedure, late recurrence (LR) within 1 year, and very LR (VLR) occurring beyond 1 year. ER has emerged as a significant predictor of LR, contrary to the traditional understanding. LR is primarily caused by PV reconnection, while VLR more involves non-PV triggers or substrates. Managing AF recurrence includes antiarrhythmic drugs, steroids, colchicine, and repeat ablation. Antiarrhythmic drugs reduce ER but have a limited impact on LR. Steroids have been shown to reduce ER, but not long-term recurrence. Colchicine, an anti-inflammatory agent, shows promise in reducing both ER and LR, although further research is necessary. Whether to perform early repeat ablation after ER remains uncertain, as not all patients require immediate intervention. In conclusion, AF recurrence after ablation remains a complex issue. Understanding the underlying mechanisms is essential for personalized management. Tailored approaches, considering individual characteristics, are crucial for long-term success. Future research should focus on improving therapeutic strategies for AF recurrence.
- 31 October 2023
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 5 (4) , 102-112
Open AccessDecision-making for recurrent atrial fibrillation after catheter ablation
Catheter ablation for atrial fibrillation (AF), especially pulmonary vein (PV) isolation, is widely used for rhythm control. However, AF recurrence remains a challenge, affecting 20% to 50% of cases. This review focuses on AF recurrence after catheter ablation. AF recurrence can be categorized into early recurrence (ER) within 3 months after index procedure, late recurrence (LR) within 1 year, and very LR (VLR) occurring beyond 1 year. ER has emerged as a significant predictor of LR, contrary to the traditional understanding. LR is primarily caused by PV reconnection, while VLR more involves non-PV triggers or substrates. Managing AF recurrence includes antiarrhythmic drugs, steroids, colchicine, and repeat ablation. Antiarrhythmic drugs reduce ER but have a limited impact on LR. Steroids have been shown to reduce ER, but not long-term recurrence. Colchicine, an anti-inflammatory agent, shows promise in reducing both ER and LR, although further research is necessary. Whether to perform early repeat ablation after ER remains uncertain, as not all patients require immediate intervention. In conclusion, AF recurrence after ablation remains a complex issue. Understanding the underlying mechanisms is essential for personalized management. Tailored approaches, considering individual characteristics, are crucial for long-term success. Future research should focus on improving therapeutic strategies for AF recurrence.
- Open Access
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (10) , 693-707
Clinical and Genetic Features of Korean Inherited Arrhythmia Probands
Jeong JH, et al. Korean Circ J. 2023 Aug;53:e56. https://doi.org/10.4070/kcj.2023.0083
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (10) , 693-707
Open AccessClinical and Genetic Features of Korean Inherited Arrhythmia Probands
Jeong JH, et al. Korean Circ J. 2023 Aug;53:e56. https://doi.org/10.4070/kcj.2023.0083
- Open Access
- 5 October 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (42) , e305
Comparison of Factors Associated With Direct Versus Transferred-in Admission to Government-Designated Regional Centers Between Acute Ischemic Stroke and Myocardial Infarction in Korea
Kim DH, et al. J Korean Med Sci. 2022 Oct;37(42):e305. https://doi.org/10.3346/jkms.2022.37.e305
- 5 October 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (42) , e305
Open AccessComparison of Factors Associated With Direct Versus Transferred-in Admission to Government-Designated Regional Centers Between Acute Ischemic Stroke and Myocardial Infarction in Korea
Kim DH, et al. J Korean Med Sci. 2022 Oct;37(42):e305. https://doi.org/10.3346/jkms.2022.37.e305
- Open Access
- 3 May 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (9) , e023214
Comparisons of Prehospital Delay and Related Factors Between Acute Ischemic Stroke and Acute Myocardial Infarction
Background: Prehospital delay is an important contributor to poor outcomes in both acute ischemic stroke (AIS) and acute myocardial infarction (AMI). We aimed to compare the prehospital delay and related factors between AIS and AMI. Methods and Results: We identified patients with AIS and AMI who were admitted to the 11 Korean Regional Cardiocerebrovascular Centers via the emergency room between July 2016 and December 2018. Delayed arrival was defined as a prehospital delay of >3 hours, and the generalized linear mixed‐effects model was applied to explore the effects of potential predictors on delayed arrival. This study included 17 895 and 8322 patients with AIS and AMI, respectively. The median value of prehospital delay was 6.05 hours in AIS and 3.00 hours in AMI. The use of emergency medical services was the key determinant of delayed arrival in both groups. Previous history, 1‐person household, weekday presentation, and interhospital transfer had higher odds of delayed arrival in both groups. Age and sex had no or minimal effects on delayed arrival in AIS; however, age and female sex were associated with higher odds of delayed arrival in AMI. More severe symptoms had lower odds of delayed arrival in AIS, whereas no significant effect was observed in AMI. Off‐hour presentation had higher and prehospital awareness had lower odds of delayed arrival; however, the magnitude of their effects differed quantitatively between AIS and AMI. Conclusions: The effects of some nonmodifiable and modifiable factors on prehospital delay differed between AIS and AMI. A differentiated strategy might be required to reduce prehospital delay.
- 3 May 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (9) , e023214
Open AccessComparisons of Prehospital Delay and Related Factors Between Acute Ischemic Stroke and Acute Myocardial Infarction
Background: Prehospital delay is an important contributor to poor outcomes in both acute ischemic stroke (AIS) and acute myocardial infarction (AMI). We aimed to compare the prehospital delay and related factors between AIS and AMI. Methods and Results: We identified patients with AIS and AMI who were admitted to the 11 Korean Regional Cardiocerebrovascular Centers via the emergency room between July 2016 and December 2018. Delayed arrival was defined as a prehospital delay of >3 hours, and the generalized linear mixed‐effects model was applied to explore the effects of potential predictors on delayed arrival. This study included 17 895 and 8322 patients with AIS and AMI, respectively. The median value of prehospital delay was 6.05 hours in AIS and 3.00 hours in AMI. The use of emergency medical services was the key determinant of delayed arrival in both groups. Previous history, 1‐person household, weekday presentation, and interhospital transfer had higher odds of delayed arrival in both groups. Age and sex had no or minimal effects on delayed arrival in AIS; however, age and female sex were associated with higher odds of delayed arrival in AMI. More severe symptoms had lower odds of delayed arrival in AIS, whereas no significant effect was observed in AMI. Off‐hour presentation had higher and prehospital awareness had lower odds of delayed arrival; however, the magnitude of their effects differed quantitatively between AIS and AMI. Conclusions: The effects of some nonmodifiable and modifiable factors on prehospital delay differed between AIS and AMI. A differentiated strategy might be required to reduce prehospital delay.
- Open Access
- 28 February 2022
- Published by Korean Wound Management Society in Journal of Wound Management and Research
- Vol. 18 (1) , 31-37
Effectiveness of Aspiration in Treating Cardiac Implantable Electronic Device-Induced Pocket Hematoma and Characteristics of Patients with Pocket Hematoma
Background: Pocket hematoma is the most common complication after procedures involving cardiac implantable electronic devices (CIEDs). Furthermore, pocket hematomas increase the risk of device infection. Unless severe, a pocket hematoma is usually managed conservatively because specific treatment is unavailable. Aspiration is not recommended as it can cause infection. This study explored whether lowering the risk of infection by aseptically removing the hematoma at an early stage would be possible through aspiration, investigated the effectiveness of treatment with aspiration for pocket hematoma, and analyzed the characteristics of patients with pocket hematoma.Methods: Via chart review, we retrospectively analyzed 570 patients who underwent CIED implantation or replacement between January 2011 and January 2021. Aspiration was performed only on grade 2 and 3 hematomas.Results: Pocket hematomas were identified in 80 patients (14%). Of these 80 patients, 52 (65%) were treated with aspiration only; six (7.5%), with aspiration plus surgical procedure; five (6.25%), with the surgical procedure only; and 17 (21.25%), with conservative treatment. Out of 58 patients treated with aspiration only and aspiration plus surgical procedure, 52 (89.65%) were treated with aspiration only, while six (10.34%) required more procedures (e.g., hematoma evacuation, Barovac insertion, or device reposition with flap surgery). However, none of these six patients exhibited an infection symptom possibly caused by aspiration.Conclusion: Out of 80 patients with hematoma, 58 were treated with aspiration, and none showed infection symptoms that could be caused by aspiration. This suggests that aspiration can be an effective treatment if performed aseptically.
- 28 February 2022
- Published by Korean Wound Management Society in Journal of Wound Management and Research
- Vol. 18 (1) , 31-37
Open AccessEffectiveness of Aspiration in Treating Cardiac Implantable Electronic Device-Induced Pocket Hematoma and Characteristics of Patients with Pocket Hematoma
Background: Pocket hematoma is the most common complication after procedures involving cardiac implantable electronic devices (CIEDs). Furthermore, pocket hematomas increase the risk of device infection. Unless severe, a pocket hematoma is usually managed conservatively because specific treatment is unavailable. Aspiration is not recommended as it can cause infection. This study explored whether lowering the risk of infection by aseptically removing the hematoma at an early stage would be possible through aspiration, investigated the effectiveness of treatment with aspiration for pocket hematoma, and analyzed the characteristics of patients with pocket hematoma.Methods: Via chart review, we retrospectively analyzed 570 patients who underwent CIED implantation or replacement between January 2011 and January 2021. Aspiration was performed only on grade 2 and 3 hematomas.Results: Pocket hematomas were identified in 80 patients (14%). Of these 80 patients, 52 (65%) were treated with aspiration only; six (7.5%), with aspiration plus surgical procedure; five (6.25%), with the surgical procedure only; and 17 (21.25%), with conservative treatment. Out of 58 patients treated with aspiration only and aspiration plus surgical procedure, 52 (89.65%) were treated with aspiration only, while six (10.34%) required more procedures (e.g., hematoma evacuation, Barovac insertion, or device reposition with flap surgery). However, none of these six patients exhibited an infection symptom possibly caused by aspiration.Conclusion: Out of 80 patients with hematoma, 58 were treated with aspiration, and none showed infection symptoms that could be caused by aspiration. This suggests that aspiration can be an effective treatment if performed aseptically.
- Open Access
- 1 January 2021
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 51 (9) , 752-763
Community-Dwelling Individuals with Coronary Artery Disease Have Higher Risk of Depression than the General Population in Female, But Not in Male
Korean Circulation Journal 대한심장학회지 순환기 Kim NH, et al. Korean Circ J. 2021 Sep;51(9):752-763. https://doi.org/10.4070/kcj.2021.0009
- 1 January 2021
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 51 (9) , 752-763
Open AccessCommunity-Dwelling Individuals with Coronary Artery Disease Have Higher Risk of Depression than the General Population in Female, But Not in Male
Korean Circulation Journal 대한심장학회지 순환기 Kim NH, et al. Korean Circ J. 2021 Sep;51(9):752-763. https://doi.org/10.4070/kcj.2021.0009
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (49) , e323
Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II
Oh S, et al. J Korean Med Sci. 2018 Nov;33(49):e323. https://doi.org/10.3346/jkms.2018.33.e323
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (49) , e323
Open AccessQuality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II
Oh S, et al. J Korean Med Sci. 2018 Nov;33(49):e323. https://doi.org/10.3346/jkms.2018.33.e323